These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9403512)

  • 21. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
    Mansky LM; Pearl DK; Gajary LC
    J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
    Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
    J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of CTP biosynthesis potentiate the anti-human immunodeficiency virus type 1 activity of 3TC in activated peripheral blood mononuclear cells.
    Dereuddre-Bosquet N; Roy B; Routledge K; Clayette P; Foucault G; Lepoivre M
    Antiviral Res; 2004 Jan; 61(1):67-70. PubMed ID: 14670596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HIV infection by baicalin--a flavonoid compound purified from Chinese herbal medicine.
    Li BQ; Fu T; Yan YD; Baylor NW; Ruscetti FW; Kung HF
    Cell Mol Biol Res; 1993; 39(2):119-24. PubMed ID: 7693133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of HIV replication in lymphocyte cultures of virus-positive subjects in the presence of sho-saiko-to, an oriental plant extract.
    Buimovici-Klein E; Mohan V; Lange M; Fenamore E; Inada Y; Cooper LZ
    Antiviral Res; 1990; 14(4-5):279-86. PubMed ID: 1708225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
    van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
    AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
    Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
    Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate.
    Rusconi S; De Pasquale MP; Milazzo L; Bulgheroni E; Citterio P; Kurtagic S; d'Arminio-Monforte A; Galli M
    AIDS; 1997 Sep; 11(11):1406-10. PubMed ID: 9302459
    [No Abstract]   [Full Text] [Related]  

  • 29. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
    Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
    Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer.
    Dutta T; Jain NK
    Biochim Biophys Acta; 2007 Apr; 1770(4):681-6. PubMed ID: 17276009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type.
    Hazen R; Lanier ER
    J Acquir Immune Defic Syndr; 2003 Mar; 32(3):255-8. PubMed ID: 12626884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
    Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
    Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.
    Eron JJ
    AIDS; 1996 Dec; 10 Suppl 5():S11-9. PubMed ID: 9030391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.
    Mansky LM; Bernard LC
    J Virol; 2000 Oct; 74(20):9532-9. PubMed ID: 11000223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT.
    Biswas DK; Mhashilkar AM; Ewaniuk DS; Pezza JA; Oh LM; Kannangara GS; Tius MA; Pardee AB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):426-34. PubMed ID: 9715838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
    Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
    HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
    Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese individuals with human immunodeficiency virus infection].
    Cao Y; Zhang F; Mei S; Li L; Gao M; Ding Y; Cai W
    Zhonghua Nei Ke Za Zhi; 2002 Feb; 41(2):109-13. PubMed ID: 11940307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing anti-HIV activity of antiretroviral agents in vitro using flow cytometry analysis of CEM-GFP cells infected with transfection-derived HIV-1 NL4-3.
    Frezza C; Grelli S; Federico M; Marino-Merlo F; Mastino A; Macchi B
    J Med Virol; 2016 Jun; 88(6):979-86. PubMed ID: 26519867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.